Video Experimental Relacionado
Updated: May 7, 2026

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
Inhibición de MEK para la terapia de células CAR-T: un enfoque para el síndrome de liberación de citoquinas y la
Hui Li1,2, Youming Wang1,2, Yingxiang Wang1
1Department of Hematology, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Abstract:
This study presents mitogen-activated protein kinase kinase (MEK) inhibition as a strategy for cytokine release syndrome (CRS) and secondary haemophagocytic lymphohistiocytosis (sHLH) in chimeric antigen receptor (CAR)-T therapy, utilizing MEK's regulatory actions that target macrophage activation, cytokine secretion from both macrophages and CAR-T cells, supported by evidence of unimpaired CAR-T-cell therapeutic efficacy of alleviated CAR-T-related inflammation.

